Device Trial Radar · NCT03599271
A Clinical Evaluation of the Intersect ENT Sinus Device (ASCEND)
Last checked: Nov 19, 2026Latest source record: May 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Jun 12, 2018
Primary completion
Dec 15, 2019
Study completion Dec 9, 2020
Sponsor
- Lead sponsor
- Intersect ENTNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 26, 2018
Design
- Study type
- Interventional
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of the ASCEND Study is to assess the safety, performance, and efficacy of the Intersect ENT UP Drug-Coated Device when used in chronic rhinosinusitis (CRS) patients undergoing balloon dilation of frontal sinus ostia (FSO)
Conditions
- Chronic Rhinosinusitis (Diagnosis)
Interventions
Drug-Coated DeviceDevice
3000 mcg mometasone furoate-coated sinus dilation device
Control DeviceDevice
Sinus dilation device without drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Randomized Cohort: Difference in Patency Grade of FSOTime frame: 30 days
- The Number of Participants in the PK Cohort With Successful Dilation of Attempted FSO at BaselineTime frame: Baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centers for Advanced ENT Care
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.